Psyched Wellness (CSE: PSYC) this morning issued a very brief press release related to ongoing studies. The firm has initiated yet another study on its proprietary AME-1 extract, this time with the study focused on gut health.
To be conducted through the firms contract research organization, KGK Sciences, the study will look to further examine the anti-inflammatory nature of the firms Amanita Muscaria extract, AME-1. Effectively, the study is to advance the preliminary findings that identified the extract as having such anti-inflammatory properties.
With respect to its anti-inflammatory properties, the research is to place an emphasis on gut health, whereby the compound will be examined for having properties that may enhance digestive barrier function and immunity. Such functions are impaired when gut health is damaged, which can lead to inflammation and chronic conditions. The study will lay groundwork for future preclinical research to be conducted by the company.
Psyched Wellness last traded at $0.295 on the CSE.
FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
The post Psyched Wellness Launches Study On Mushroom Extract Focused On Gut Health appeared first on the deep dive.